Does this programme prove that psychosis can be prevented?
No. Prevention of psychosis is the mission and research question. It is not presented here as an established result for NWPT’s candidate.
FAQ
Questions & answers
Combined answers on science, DeSci, financing, and governance — in plain language, with proposed items clearly labelled.
Science
What is NWPT-SM32300?
Company materials describe it as a 300 mg CBD micellar-emulsion softgel under investigation. Earlier documents may use another internal name; we reconcile naming before making detailed product claims.
Is cannabidiol already proven for CHR-P?
CBD has been studied in various contexts, but other products’ data are not NWPT-SM32300 data. Any claims for this programme must rest on evidence generated with this formulation under appropriate protocols.
Will community members or tokenholders decide the trial design?
No. Protocol, dose, endpoints, eligibility, safety, and regulatory submissions remain with the pharmaceutical sponsor and independent clinical oversight — not community or token votes.
Where can clinicians or researchers ask scientific questions?
Use the press and general contact channel on this site for routing. This is not a diagnosis service, trial enrolment portal, or medical advice line.
DeSci & “DAO”
Is this a DAO I can join and invest in on this website?
No. “NW PharmaTech DAO” is a working project name. This site is informational. There is no live investment, token sale, or wallet connection here.
Is NWPharmaTech DAO a live investment product?
“NW PharmaTech DAO” is a working project name for exploring how DeSci infrastructure might support programme financing. It does not mean a token is for sale, that a DAO legal entity already exists, or that community members own NWPT or control clinical decisions.
What is DeSci doing here?
Proposed: We are exploring whether new capital constituencies and transparent programme financing can support rigorous CHR-P research — without weakening pharmaceutical governance. Any financing would be privately placed and legally controlled.
Will tokenholders decide the clinical trial?
No. Clinical decisions remain with the pharmaceutical sponsor and independent scientific and ethical oversight.
Financing & capital
Can I invest through this website?
No. This site does not accept investments, subscriptions, or payments. Any future financing for the CHR-P programme would be a private process for legally eligible investors only, under documents that do not yet constitute an open offer.
Will there be a token?
Proposed: The working design prioritises a conventional private placement and investor register first. A permissioned token representation of that register is an optional later layer — not required to fund the programme and not available on this site. There is no DEX, public mint, or retail token sale in the current design.
What would investors buy (if financing proceeds)?
Proposed — not executed: Rights would be limited to expressly granted CHR-P programme economics through a dedicated vehicle — not NWPT parent-company equity, and not ownership of the medicine, patient data, or clinical decisions. Exact instrument terms remain under design and require counsel and corporate approvals before any offer.
Who is eligible?
Working design: First-close design assumes accredited, professional, or institutional investors as defined under the laws that apply to the chosen structure — not a retail public offering. Eligibility categories are not interchangeable across jurisdictions.
Is the ~$10 million figure an offer?
No. Approximately $10 million is a working fundraising target for planning. It is not committed capital, a validated trial budget, or a priced offer.
How would catalytic capital work if financing proceeds?
Proposed: Through a dedicated programme vehicle via a private placement to legally eligible investors, with an enforceable register. Rights would be limited to expressly granted CHR-P programme economics — not NWPT parent equity. Exact terms are under design and are not offered on this site.
Why involve DeSci / crypto-native capital at all?
Working thesis: Conventional biotech capital has often struggled with early-intervention psychiatry timelines and endpoint complexity. The project explores whether new investor constituencies (including crypto-native family offices and DeSci-aware capital) can sit alongside specialist life-sciences investors — without weakening pharmaceutical sponsor governance.
Who would be sequenced first (if a private process opens)?
Working: A credible anchor, then complementary DeSci/crypto-native and life-sciences / mission-aligned investors — all under the same eligibility and private-process rules. No allocation percentages or commitments are assumed or shown as live.
Can community members invest through a DAO on this site?
No. This site does not accept investment. “NW PharmaTech DAO” is a working project name, not a live investment product.